GL1X · GenesisL1 explorer

MolNFT v1 · #168959 · protein

Vaccine-elicited mouse fp-targeting neutralizing antibody VFP16.02 with S48K mutation in light chain in complex with HIV fusion peptide (residue 512-519)

6WWC · VFP16.02 antibody heavy chain: “Vaccine-elicited mouse fp-targeting neutralizing antibody VFP16.02 with S48K mutation in light chain in…”. X-ray diffraction, 9 pockets (best druggability 0.68). MolNFT v1 #168959 on GenesisL1: 3D…

PDB
6WWC
Type
protein
Length
878 residues
Chains
6
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
VFP16.02 antibody heavy chain; VFP16.02 antibody light chain; Fusion peptide
Pockets
9 · best druggability 0.68

Structure

x-ray diffraction · 3 distinct chains · 5% helix, 52% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, DVFP16.02 antibody heavy chainprotein2136% helix, 52% strand—
B, HVFP16.02 antibody light chainprotein2185% helix, 55% strand—
C, FFusion peptideprotein80% helix, 0% strand—

Pockets

9 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
17200.680.7656empty
27800.680.7558empty
34060.640.7858empty
4630.510.8619empty
51900.430.7331empty

Interfaces

8 interfaces between chains.

  • D–H · 1879 Ų buried · 10 hydrogen bonds · protein-protein
  • A–B · 1839 Ų buried · 11 hydrogen bonds · protein-protein
  • B–D · 772 Ų buried · 16 hydrogen bonds · protein-protein
  • D–F · 342 Ų buried · 7 hydrogen bonds · protein-protein
  • A–C · 342 Ų buried · 8 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 8 disulfide (disulfide).

Compared structures

  • 6WWC · Vaccine-elicited mouse FP-targeting neutralizing antibody vFP16.02 with S48K mutation in… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.